دورية أكاديمية
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
| العنوان: | A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients. |
|---|---|
| المؤلفون: | Yu ZP; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Ding JH; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Sun AN; Hematology Division, Soochow University Affiliated No 1 People's Hospital, Suzhou, China., Chen BA; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Ge Z; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Wu DP; Hematology Division, Soochow University Affiliated No 1 People's Hospital, Suzhou, China. |
| المصدر: | Stem cells and development [Stem Cells Dev] 2019 Oct 15; Vol. 28 (20), pp. 1376-1383. Date of Electronic Publication: 2019 Sep 26. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101197107 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8534 (Electronic) Linking ISSN: 15473287 NLM ISO Abbreviation: Stem Cells Dev Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c2004- |
| مواضيع طبية MeSH: | Cord Blood Stem Cell Transplantation* , Immune Reconstitution*, Anemia, Aplastic/*drug therapy , Leukemia, Myeloid, Acute/*drug therapy , Myelodysplastic Syndromes/*drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Primary Immunodeficiency Diseases/*drug therapy , Transplantation Conditioning/*methods, Adult ; Anemia, Aplastic/immunology ; Anemia, Aplastic/mortality ; Anemia, Aplastic/pathology ; Antilymphocyte Serum/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Busulfan/administration & dosage ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Female ; Graft Survival ; Graft vs Host Disease/physiopathology ; Graft vs Host Disease/prevention & control ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Immunosuppressive Agents/therapeutic use ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myelodysplastic Syndromes/immunology ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Primary Immunodeficiency Diseases/immunology ; Primary Immunodeficiency Diseases/mortality ; Primary Immunodeficiency Diseases/pathology ; Semustine/administration & dosage ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Unrelated Donors ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives |
| مستخلص: | This study included data from 81 consecutively enrolled patients with hematological diseases who had been treated with unrelated umbilical cord blood transplantation (UCBT) between September 2014 and April 2019. All patients received intense conditioning regimens with combined fludarabine and high-dose cyclophosphamide (FC) before undergoing UCBT. Sixty-seven patients received a single UCBT, and 14 patients received a double UCBT. Fifty patients were pretreated with the fludarabine, busulfan, and cyclophosphamide (FBC) protocol, while 31 patients were treated with FC before transplantation. Graft-versus-host disease (GVHD) was prevented with cyclosporine A and mycophenolate mofetil administration. According to low-resolution, human leukocyte antigen (HLA) donor-recipient matching at six sites, 53 patients had 5-6 matches, while 28 patients had 4 matches. Seventy-eight patients (96.3%) achieved complete engraftment in this study. Thirty-six patients developed acute GVHD (aGVHD). The cumulative incidence of grade I-II aGVHD at day 100 posthematopoietic stem cell transplantation was 29.6%, and the cumulative incidence of grade III-IV aGVHD was 14.8%. At the end of the follow-up, 12 patients died due to treatment-related complications, and 4 died of disease relapse after transplantation. The transplant-related deaths were due to transplant-related infection (8 of 81), GVHD (2 of 81), and organ toxicity (2 of 81). The probability of overall survival (OS) was 80.2%. A higher dose of cyclophosphamide combined with fludarabine conditioning in UCBT was an effective curative method for treatment of hematologic disorders and could enhance the engraftment of umbilical cord blood stem cells, promote post-transplant immune reconstitution, and improve OS. |
| فهرسة مساهمة: | Keywords: Allo-hematopoietic stem cell transplantation; cord blood transplantation; hematologic system diseases |
| المشرفين على المادة: | 0 (Antilymphocyte Serum) 0 (Immunosuppressive Agents) 04079A1RDZ (Cytarabine) 13909-09-6 (Semustine) 143011-72-7 (Granulocyte Colony-Stimulating Factor) 8N3DW7272P (Cyclophosphamide) FA2DM6879K (Vidarabine) G1LN9045DK (Busulfan) P2K93U8740 (fludarabine) |
| تواريخ الأحداث: | Date Created: 20190830 Date Completed: 20200723 Latest Revision: 20200723 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1089/scd.2019.0139 |
| PMID: | 31464164 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-8534 |
|---|---|
| DOI: | 10.1089/scd.2019.0139 |